BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $338,546 | -22.1% | 8,970 | -5.9% | 0.04% | -18.8% |
| Q2 2023 | $434,505 | -3.5% | 9,537 | -14.1% | 0.05% | -9.4% |
| Q1 2023 | $450,111 | -25.0% | 11,097 | -5.8% | 0.05% | -28.4% |
| Q4 2022 | $600,426 | -8.6% | 11,780 | -3.4% | 0.07% | -16.9% |
| Q3 2022 | $657,000 | -13.4% | 12,194 | +3.2% | 0.09% | -16.8% |
| Q2 2022 | $759,000 | -19.8% | 11,818 | -3.2% | 0.11% | -4.5% |
| Q1 2022 | $946,000 | -15.9% | 12,204 | -6.9% | 0.11% | -11.1% |
| Q4 2021 | $1,125,000 | -11.5% | 13,107 | -17.1% | 0.13% | -19.7% |
| Q3 2021 | $1,271,000 | -7.8% | 15,806 | -7.7% | 0.16% | -6.5% |
| Q2 2021 | $1,378,000 | -68.2% | 17,121 | -66.7% | 0.17% | -70.5% |
| Q1 2021 | $4,338,000 | +0.2% | 51,434 | -4.7% | 0.57% | -5.2% |
| Q4 2020 | $4,329,000 | +0.4% | 53,945 | +0.6% | 0.60% | -11.4% |
| Q3 2020 | $4,313,000 | -4.0% | 53,629 | +2.7% | 0.68% | -11.6% |
| Q2 2020 | $4,495,000 | +7.6% | 52,203 | +1.4% | 0.77% | -12.3% |
| Q1 2020 | $4,179,000 | -0.3% | 51,468 | +2.6% | 0.88% | +25.7% |
| Q4 2019 | $4,193,000 | -5.2% | 50,144 | -0.8% | 0.70% | -11.0% |
| Q3 2019 | $4,423,000 | +6.5% | 50,569 | -0.2% | 0.78% | +4.1% |
| Q2 2019 | $4,152,000 | +0.8% | 50,693 | +0.0% | 0.75% | -4.0% |
| Q1 2019 | $4,120,000 | +36.3% | 50,668 | +10.3% | 0.78% | +6.0% |
| Q4 2018 | $3,023,000 | -18.5% | 45,932 | -4.5% | 0.74% | +6.5% |
| Q3 2018 | $3,708,000 | +7.0% | 48,102 | +2.5% | 0.69% | +1.0% |
| Q2 2018 | $3,464,000 | +16.4% | 46,914 | +2.5% | 0.69% | +13.0% |
| Q1 2018 | $2,976,000 | -25.8% | 45,764 | -26.3% | 0.61% | -2.4% |
| Q4 2017 | $4,013,000 | +38.0% | 62,080 | +33.9% | 0.62% | -2.7% |
| Q3 2017 | $2,909,000 | +3.0% | 46,357 | -0.6% | 0.64% | -0.3% |
| Q2 2017 | $2,825,000 | +66.5% | 46,657 | +54.9% | 0.64% | +22.8% |
| Q1 2017 | $1,697,000 | +29.8% | 30,122 | +2.2% | 0.52% | +23.7% |
| Q4 2016 | $1,307,000 | -4.9% | 29,471 | +2.0% | 0.42% | -2.3% |
| Q3 2016 | $1,375,000 | +19.8% | 28,881 | +13.8% | 0.43% | +17.7% |
| Q2 2016 | $1,148,000 | +32.9% | 25,380 | +20.7% | 0.37% | +30.1% |
| Q1 2016 | $864,000 | +16.0% | 21,030 | +7.7% | 0.28% | +13.7% |
| Q4 2015 | $745,000 | +10.7% | 19,530 | -4.6% | 0.25% | +9.7% |
| Q3 2015 | $673,000 | -52.4% | 20,480 | +1.4% | 0.23% | -48.4% |
| Q2 2015 | $1,413,000 | +4.7% | 20,205 | +2.5% | 0.44% | +6.3% |
| Q1 2015 | $1,350,000 | +27.2% | 19,705 | +36.2% | 0.41% | +0.5% |
| Q4 2014 | $1,061,000 | -16.8% | 14,470 | -18.6% | 0.41% | +3.8% |
| Q3 2014 | $1,276,000 | +48.0% | 17,775 | +49.1% | 0.40% | +50.8% |
| Q2 2014 | $862,000 | +52.6% | 11,925 | +55.4% | 0.26% | +48.0% |
| Q1 2014 | $565,000 | – | 7,675 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |